Calcium Phosphate Ceramic Systems in Growth Factor and Drug Delivery for Bone Tissue Engineering: a Review

Overview

Journal Acta Biomater

Publisher Elsevier

Specialty Biomedical Engineering

Date 2011 Dec 1

PMID 22127225

Citations 202

Authors

Susmita Bose

Solaiman Tarafder

Affiliations

Soon will be listed here.

Abstract

Calcium phosphates (CaPs) are the most widely used bone substitutes in bone tissue engineering due to their compositional similarities to bone mineral and excellent biocompatibility. In recent years, CaPs, especially hydroxyapatite and tricalcium phosphate, have attracted significant interest in simultaneous use as bone substitute and drug delivery vehicle, adding a new dimension to their application. CaPs are more biocompatible than many other ceramic and inorganic nanoparticles. Their biocompatibility and variable stoichiometry, thus surface charge density, functionality, and dissolution properties, make them suitable for both drug and growth factor delivery. CaP matrices and scaffolds have been reported to act as delivery vehicles for growth factors and drugs in bone tissue engineering. Local drug delivery in musculoskeletal disorder treatments can address some of the critical issues more effectively and efficiently than the systemic delivery. CaPs are used as coatings on metallic implants, CaP cements, and custom designed scaffolds to treat musculoskeletal disorders. This review highlights some of the current drug and growth factor delivery approaches and critical issues using CaP particles, coatings, cements, and scaffolds towards orthopedic and dental applications.

Citing Articles

In Situ Application of Berberine-Loaded Liposomes on the Treatment of Osteomyelitis.

Wang S, Zhao T, Sun Y, Li S, Lu D, Qiu M ACS Omega. 2025; 10(7):7350-7361.

PMID: 40028119 PMC: 11866016. DOI: 10.1021/acsomega.4c11198.

Nano-hydroxyapatite/natural polymer composite scaffolds for bone tissue engineering: a brief review of recent trend.

Radha G, Manjubaashini N, Balakumar S In Vitro Model. 2025; 2(5):125-151.

PMID: 39872168 PMC: 11756495. DOI: 10.1007/s44164-023-00049-w.

Evaluation of calcium phosphate-coated polycaprolactone/graphene oxide scaffold with macro- and microporous structure for bone tissue engineering.

Kim S, Kim N, Park S, Choi J, Song Y, Tumursukh N In Vitro Model. 2025; 1(3):261-272.

PMID: 39871868 PMC: 11756476. DOI: 10.1007/s44164-022-00026-9.

3D scaffold of hydroxyapatite/β tricalcium phosphate from mussel shells: Synthesis, characterization and cytotoxicity.

Fonseca S, Freitas R, Sotiles A, Schemczssen-Graeff Z, Miranda I, Biscaia S Heliyon. 2025; 11(1):e41585.

PMID: 39866499 PMC: 11758959. DOI: 10.1016/j.heliyon.2024.e41585.

Calcium Phosphate Nanoparticles Functionalized with a Cardio-Specific Peptide.

Mancini F, Degli Esposti L, Adamiano A, Modica J, Catalucci D, Mehn D Nanomaterials (Basel). 2025; 15(2.

PMID: 39852709 PMC: 11767714. DOI: 10.3390/nano15020094.

References

Kim H, Knowles J, Kim H . Hydroxyapatite/poly(epsilon-caprolactone) composite coatings on hydroxyapatite porous bone scaffold for drug delivery. Biomaterials. 2003; 25(7-8):1279-87. DOI: 10.1016/j.biomaterials.2003.07.003. View

Roelofs A, Thompson K, Gordon S, Rogers M . Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006; 12(20 Pt 2):6222s-6230s. DOI: 10.1158/1078-0432.CCR-06-0843. View

Stallmann H, De Roo R, Faber C, Nieuw Amerongen A, Wuisman P . In vivo release of the antimicrobial peptide hLF1-11 from calcium phosphate cement. J Orthop Res. 2007; 26(4):531-8. DOI: 10.1002/jor.20511. View

Roy M, Bandyopadhyay A, Bose S . Induction Plasma Sprayed Nano Hydroxyapatite Coatings on Titanium for Orthopaedic and Dental Implants. Surf Coat Technol. 2011; 205(8-9):2785-2792. PMC: 3086534. DOI: 10.1016/j.surfcoat.2010.10.042. View

Schafer P, Fink B, Sandow D, Margull A, Berger I, Frommelt L . Prolonged bacterial culture to identify late periprosthetic joint infection: a promising strategy. Clin Infect Dis. 2008; 47(11):1403-9. DOI: 10.1086/592973. View

Adair J, Parette M, Altinoglu E, Kester M . Nanoparticulate alternatives for drug delivery. ACS Nano. 2010; 4(9):4967-70. DOI: 10.1021/nn102324e. View

Rey C . Calcium phosphate biomaterials and bone mineral. Differences in composition, structures and properties. Biomaterials. 1990; 11:13-5. View

Fu H, Hu Y, McNelis T, Hollinger J . A calcium phosphate-based gene delivery system. J Biomed Mater Res A. 2005; 74(1):40-8. DOI: 10.1002/jbm.a.30267. View

Girod Fullana S, Ternet H, Freche M, Lacout J, Rodriguez F . Controlled release properties and final macroporosity of a pectin microspheres-calcium phosphate composite bone cement. Acta Biomater. 2009; 6(6):2294-300. DOI: 10.1016/j.actbio.2009.11.019. View

10.

Durucan C, Brown P . Low temperature formation of calcium-deficient hydroxyapatite-PLA/PLGA composites. J Biomed Mater Res. 2000; 51(4):717-25. DOI: 10.1002/1097-4636(20000915)51:4<717::aid-jbm21>3.0.co;2-q. View

11.

Ramay H, Zhang M . Biphasic calcium phosphate nanocomposite porous scaffolds for load-bearing bone tissue engineering. Biomaterials. 2004; 25(21):5171-80. DOI: 10.1016/j.biomaterials.2003.12.023. View

12.

Sun L, Chow L, Frukhtbeyn S, Bonevich J . Preparation and Properties of Nanoparticles of Calcium Phosphates With Various Ca/P Ratios. J Res Natl Inst Stand Technol. 2010; 115(4):243-255. PMC: 2965602. DOI: 10.6028/jres.115.018. View

13.

Blom E, Klein-Nulend J, Wolke J, van Waas M, Driessens F, Burger E . Transforming growth factor-beta1 incorporation in a calcium phosphate bone cement: material properties and release characteristics. J Biomed Mater Res. 2001; 59(2):265-72. DOI: 10.1002/jbm.1241. View

14.

Maitra A . Calcium phosphate nanoparticles: second-generation nonviral vectors in gene therapy. Expert Rev Mol Diagn. 2005; 5(6):893-905. DOI: 10.1586/14737159.5.6.893. View

15.

Yao G, Wang L, Wu Y, Smith J, Xu J, Zhao W . FloDots: luminescent nanoparticles. Anal Bioanal Chem. 2006; 385(3):518-24. DOI: 10.1007/s00216-006-0452-z. View

16.

Ratier A, Gibson I, Best S, Freche M, Lacout J, Rodriguez F . Setting characteristics and mechanical behaviour of a calcium phosphate bone cement containing tetracycline. Biomaterials. 2001; 22(9):897-901. DOI: 10.1016/s0142-9612(00)00252-0. View

17.

Kuboki Y, Jin Q, Takita H . Geometry of carriers controlling phenotypic expression in BMP-induced osteogenesis and chondrogenesis. J Bone Joint Surg Am. 2001; 83-A Suppl 1(Pt 2):S105-15. View

18.

Hossain M, Irwin R, Baumann M, McCabe L . Hepatocyte growth factor (HGF) adsorption kinetics and enhancement of osteoblast differentiation on hydroxyapatite surfaces. Biomaterials. 2004; 26(15):2595-602. DOI: 10.1016/j.biomaterials.2004.07.051. View

19.

Li Y, Weng W, Tam K . Novel highly biodegradable biphasic tricalcium phosphates composed of alpha-tricalcium phosphate and beta-tricalcium phosphate. Acta Biomater. 2006; 3(2):251-4. DOI: 10.1016/j.actbio.2006.07.003. View

20.

Martin I, Muraglia A, Campanile G, Cancedda R, Quarto R . Fibroblast growth factor-2 supports ex vivo expansion and maintenance of osteogenic precursors from human bone marrow. Endocrinology. 1997; 138(10):4456-62. DOI: 10.1210/endo.138.10.5425. View